Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (978)	8/1/2000 12:59:32 PM
From: Ian@SI	Read Replies (1) \| Respond to of 1321

Zeev, It takes about 3 or 4 treatments during the first year and another 2 or 3 treatments during the 2nd year to treat the condition for each of the 500,000 new patients diagnosed with the condition annually. Note that 500,000 is the worldwide figure (or at least the developed portion of the world where such a medical diagnosis would be available). The number is growing due to the boomers - increased number of people over age 50. No stats are yet available (to the public at least) regarding treatment frequency, if any, after the 2nd year. Good conference call except for the parts where answers were deferred to an upcoming analyst's meeting - 2 weeks from now. I suspect the stock price might do very good things in the interim in anticipation of the juicy guidance that may be on the way. Ian.